einstein (São Paulo). 01/Jan/2017;15(1):1-3.

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Ekaterini Simões Goudouris, Almerinda Maria do Rego Silva, Aluce Loureiro Ouricuri, Anete Sevciovic Grumach, Antonio Condino Neto, Beatriz Tavares Costa-Carvalho, Carolina Cardoso de Mello Prando, Cristina Maria Kokron, Dewton de Moraes Vasconcelos, Fabíola Scancetti Tavares, Gesmar Rodrigues Silva Segundo, Irma Cecília Douglas Paes Barreto, Mayra de Barros Dorna, Myrthes Anna Maragna Toledo Barros, Wilma Carvalho Neves Forte

DOI: 10.1590/S1679-45082017AE3844

ABSTRACT

In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Comments